{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T03:09:08Z","timestamp":1784862548155,"version":"3.55.0"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T00:00:00Z","timestamp":1647561600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.vaccine.2022.03.027","type":"journal-article","created":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T08:02:57Z","timestamp":1648540977000},"page":"A113-A121","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"S1","title":["Review of use of inactivated poliovirus vaccine in campaigns to control type 2 circulating vaccine derived poliovirus (cVDPV) outbreaks"],"prefix":"10.1016","volume":"41","author":[{"given":"Concepcion F.","family":"Estivariz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie D.","family":"Kovacs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ondrej","family":"Mach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2022.03.027_b0005","unstructured":"World Health Organization. Global circulating vaccine-derived poliovirus cases, 2000-2018. Available at http:\/\/polioeradication.org\/polio-today\/polio-now\/this-week\/circulating-vaccine-derived-poliovirus. Accessed 16 December 2021."},{"key":"10.1016\/j.vaccine.2022.03.027_b0010","doi-asserted-by":"crossref","first-page":"258","DOI":"10.3201\/eid2302.161210","article-title":"Estimated effect of inactivated poliovirus vaccine campaigns, Nigeria and Pakistan, January 2014-April 2016","volume":"23","author":"Shirreff","year":"2017","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2022.03.027_b0015","unstructured":"World Health Organization. Meeting of the Strategic Advisory Group of Experts on Immunization, 31 March - 1 April 2020: conclusions and recommendations. Wkly Epidemiol Rec. 2020;95:241-56"},{"key":"10.1016\/j.vaccine.2022.03.027_b0020","unstructured":"World Health Organization. Meeting of the Strategic Advisory Group of Experts on immunization, October 2020 - conclusions and recommendations. Wkly Epidemiol Rec. 2020;92:301-20"},{"key":"10.1016\/j.vaccine.2022.03.027_b0025","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1093\/oxfordjournals.aje.a009924","article-title":"Transmissibility and persistence of oral polio vaccine viruses: implications for the global poliomyelitis eradication initiative","volume":"150","author":"Fine","year":"1999","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2022.03.027_b0030","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1093\/clinids\/2.3.352","article-title":"Viral vaccination via the mucosal routes","volume":"2","author":"Ogra","year":"1980","journal-title":"Rev Infect Dis"},{"key":"10.1016\/j.vaccine.2022.03.027_b0035","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1749-6632.1995.tb44462.x","article-title":"Defining surrogate serologic tests with respect to predicting protective vaccine efficacy: poliovirus vaccination","volume":"754","author":"Sutter","year":"1995","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.vaccine.2022.03.027_b0040","series-title":"First International Conference on live poliovirus vaccines","first-page":"203","article-title":"Revised preliminary report on the Louisiana observations of the natural spread within families of living vaccine strains of poliovirus","author":"Gelfand","year":"1959"},{"key":"10.1016\/j.vaccine.2022.03.027_b0045","first-page":"265","article-title":"Comparison of the resistance of the intestinal tract ot poliomyelitis virus (Sabin's strains) in persons after naturally and experimentally acquired immunity","volume":"5","author":"Ghendon","year":"1961","journal-title":"Acta Virol"},{"key":"10.1016\/j.vaccine.2022.03.027_b0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/infdis\/163.1.1","article-title":"Mucosal immunity induced by enhanced-potency inactivated and oral polio vaccines","volume":"163","author":"Onorato","year":"1991","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2022.03.027_b0055","series-title":"Measles and poliomyelitis","first-page":"279","article-title":"Inactivated and live, attenuated poliovirus vaccines: mucosal immunity","author":"Sutter","year":"1993"},{"key":"10.1016\/j.vaccine.2022.03.027_b0060","first-page":"e1002599","article-title":"Systematic review of mucosal immunity induced by oral and inactivated poliovirus vaccines against virus shedding following oral poliovirus challenge","volume":"8","author":"Hird","year":"2012"},{"key":"10.1016\/j.vaccine.2022.03.027_b0065","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1126\/science.1255006","article-title":"Polio eradication. efficacy of inactivated poliovirus vaccine in India","volume":"345","author":"Jafari","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2022.03.027_b0070","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/S0140-6736(14)60934-X","article-title":"Effect of a single inactivated poliovirus vaccine dose on intestinal immunity against poliovirus in children previously given oral vaccine: an open-label, randomised controlled trial","volume":"384","author":"John","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2022.03.027_b0075","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1093\/oxfordjournals.aje.a120717","article-title":"Studies of the immunogenicity, communicability and genetic stability of oral poliovaccine administered during the winter","volume":"86","author":"Benyesh-Melnick","year":"1967","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2022.03.027_b0080","first-page":"495","article-title":"Oral poliovirus vaccine in tropical Africa: greater impact on incidence of paralytic disease than expected from coverage surveys and seroconversion rates","volume":"65","author":"Heymann","year":"1987","journal-title":"Bull World Health Organ"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2022.03.027_b0085","doi-asserted-by":"crossref","first-page":"S380","DOI":"10.1093\/infdis\/jiu184","article-title":"Vaccine-associated paralytic poliomyelitis: a review of the epidemiology and estimation of the global burden","volume":"210","author":"Platt","year":"2014","journal-title":"J Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2022.03.027_b0090","doi-asserted-by":"crossref","first-page":"S283","DOI":"10.1093\/infdis\/jiu295","article-title":"Vaccine-derived polioviruses","volume":"210","author":"Burns","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2022.03.027_b0095","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1126\/science.aba1238","article-title":"Evolving epidemiology of poliovirus serotype 2 following withdrawal of the serotype 2 oral poliovirus vaccine","volume":"368","author":"Macklin","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2022.03.027_b0100","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.coviro.2013.05.007","article-title":"Poliovirus vaccination options for achieving eradication and securing the endgame","volume":"3","author":"Est\u00edvariz","year":"2013","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.vaccine.2022.03.027_b0105","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1093\/clinids\/13.5.926","article-title":"Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review","volume":"13","author":"Patriarca","year":"1991","journal-title":"Rev Infect Dis"},{"key":"10.1016\/j.vaccine.2022.03.027_b0110","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1016\/j.vaccine.2015.04.055","article-title":"Immunogenicity of poliovirus vaccines in chronically malnourished infants: a randomized controlled trial in Pakistan","volume":"33","author":"Saleem","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.03.027_b0115","series-title":"Measles and Poliomyelitis","first-page":"267","article-title":"Poliovirus vaccine formulations","author":"Patriarca","year":"1993"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2022.03.027_b0120","doi-asserted-by":"crossref","first-page":"S183","DOI":"10.1093\/infdis\/175.Supplement_1.S183","article-title":"National immunization days: state of the art","volume":"175","author":"Birmingham","year":"1997","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2022.03.027_b0125","doi-asserted-by":"crossref","unstructured":"el-Sayed N, el-Gamal Y, Abbassy AA, Seoud I, Salama M, Kandeel A, et al. Monovalent type 1 oral poliovirus vaccine in newborns. N Engl J Med. 2008;359:1655-65","DOI":"10.1056\/NEJMoa0800390"},{"key":"10.1016\/j.vaccine.2022.03.027_b0130","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/S1473-3099(15)00094-8","article-title":"Immunogenicity of three doses of bivalent, trivalent, or type 1 monovalent oral poliovirus vaccines with a 2 week interval between doses in Bangladesh: an open-label, non-inferiority, randomised, controlled trial","volume":"5","author":"Est\u00edvariz","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2022.03.027_b0135","doi-asserted-by":"crossref","first-page":"5793","DOI":"10.1016\/j.vaccine.2011.04.133","article-title":"Monovalent type 1 oral poliovirus vaccine among infants in India: report of two randomized double-blind controlled clinical trials","volume":"29","author":"John","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.03.027_b0140","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1016\/S0140-6736(10)61230-5","article-title":"Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double-blind, controlled trial","volume":"376","author":"Sutter","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2022.03.027_b0145","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S1473-3099(18)30113-0","article-title":"Immunogenicity of type 2 monovalent oral and inactivated poliovirus vaccines for type 2 poliovirus outbreak response: an open-label, randomised controlled trial","volume":"18","author":"Zaman","year":"2018","journal-title":"Lancet Infect Dis."},{"key":"10.1016\/j.vaccine.2022.03.027_b0150","unstructured":"Centers for Disease Control and Prevention. Progress toward interruption of wild poliovirus transmission - worldwide, 2009. MMWR Morb Mortal Wkly Rep. 2010;59:545-50"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2022.03.027_b0155","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1093\/infdis\/jiu456","article-title":"Progress toward global interruption of wild poliovirus transmission, 2010\u20132013, and tackling the challenges to complete eradication","volume":"210","author":"Wassilak","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2022.03.027_b0160","first-page":"941","article-title":"Polio-free certification and lessons learned\u2013South-East Asia region, March 2014","volume":"63","author":"Bahl","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2022.03.027_b0165","doi-asserted-by":"crossref","first-page":"S439","DOI":"10.1093\/infdis\/jit601","article-title":"Immunogenicity and effectiveness of routine immunization with 1 or 2 doses of inactivated poliovirus vaccine: systematic review and meta-analysis","volume":"210","author":"Grassly","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2022.03.027_b0170","doi-asserted-by":"crossref","unstructured":"Anand A, Zaman K, Estivariz CF, Yunus M, Gary H, E., Weldon WC, et al. Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: A randomized controlled trial. Vaccine. 2015;33:6816-22","DOI":"10.1016\/j.vaccine.2015.09.039"},{"key":"10.1016\/j.vaccine.2022.03.027_b0175","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1016\/S0140-6736(19)30503-3","article-title":"Immunogenicity of full and fractional dose of inactivated poliovirus vaccine for use in routine immunisation and outbreak response: an open-label, randomised controlled trial","volume":"393","author":"Snider","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2022.03.027_b0180","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJMoa1202541","article-title":"Priming after a fractional dose of inactivated poliovirus vaccine","volume":"368","author":"Resik","year":"2013","journal-title":"New Eng J Med"},{"key":"10.1016\/j.vaccine.2022.03.027_b0185","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S1473-3099(20)30555-7","article-title":"Safety and immunogenicity of inactivated poliovirus vaccine schedules for the post-eradication era: a randomised open-label, multicentre, phase 3, non-inferiority trial","volume":"21","author":"Bandyopadhyay","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2022.03.027_b0190","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/S1473-3099(19)30301-9","article-title":"Vaccine schedules and the effect on humoral and intestinal immunity against poliovirus: a systematic review and network meta-analysis","volume":"19","author":"Macklin","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2022.03.027_b0195","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/infdis\/jix577","article-title":"Immunogenicity of different routine poliovirus vaccination schedules: a randomized, controlled trial in Karachi, Pakistan","volume":"217","author":"Saleem","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2022.03.027_b0200","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1093\/cid\/cix381","article-title":"The immunogenicity of fractional intradermal doses of the inactivated poliovirus vaccine is associated with the size of the intradermal fluid bleb","volume":"65","author":"Bibby","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2022.03.027_b0205","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1016\/S0264-410X(02)00523-6","article-title":"Serological response and poliovirus excretion following different combined oral and inactivated poliovirus vaccines immunization schedules","volume":"21","author":"Parent du Chatelet","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.03.027_b0210","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1016\/S0140-6736(15)00237-8","article-title":"Immunogenicity of a new routine vaccination schedule for global poliomyelitis prevention: an open-label, randomised controlled trial","volume":"386","author":"Sutter","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2022.03.027_b0215","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S0140-6736(16)00703-0","article-title":"Humoral and intestinal immunity induced by new schedules of bivalent oral poliovirus vaccine and one or two doses of inactivated poliovirus vaccine in Latin American infants: an open-label randomised controlled trial","volume":"388","author":"Asturias","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2022.03.027_b0220","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1016\/j.vaccine.2017.04.041","article-title":"Inactivated polio vaccines from three different manufacturers have equivalent safety and immunogenicity when given as 1 or 2 additional doses after bivalent OPV: results from a randomized controlled trial in Latin America","volume":"35","author":"Lopez-Medina","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.03.027_b0225","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S1473-3099(15)00488-0","article-title":"Immunogenicity and safety of a novel monovalent high-dose inactivated poliovirus type 2 vaccine in infants: a comparative, observer-blind, randomised, controlled trial","volume":"16","author":"Saez-Llorens","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2022.03.027_b0230","doi-asserted-by":"crossref","unstructured":"Moriniere BJ, van Loon FP, Rhodes PH, Klein-Zabban ML, Frank-Senat B, Herrington JE, et al. Immunogenicity of a supplemental dose of oral versus inactivated poliovirus vaccine Lancet. 1993;341:1545-50","DOI":"10.1016\/0140-6736(93)90693-B"},{"key":"10.1016\/j.vaccine.2022.03.027_b0235","doi-asserted-by":"crossref","unstructured":"Hanlon P, Hanlon L, Marsh V, Byass P, Sillah H, Hayes R, et al. Serological comparisons of approaches to polio vaccination in the Gambia Lancet. 1987;1:800-1","DOI":"10.1016\/S0140-6736(87)92818-2"},{"key":"10.1016\/j.vaccine.2022.03.027_b0240","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1056\/NEJM200009143431103","article-title":"Trial of a supplemental dose of four poliovirus vaccines","volume":"343","author":"Sutter","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2022.03.027_b0245","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.vaccine.2014.11.025","article-title":"Immune responses after fractional doses of inactivated poliovirus vaccine using newly developed intradermal jet injectors: a randomized controlled trial in Cuba","volume":"33","author":"Resik","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.03.027_b0250","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/S1473-3099(11)70190-6","article-title":"Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6\u20139 months in Moradabad, India: a community-based, randomised controlled trial","volume":"12","author":"Estivariz","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2022.03.027_b0255","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1016\/j.vaccine.2018.02.051","article-title":"Evaluation of vaccine derived poliovirus type 2 outbreak response options: a randomized controlled trial, Karachi, Pakistan","volume":"36","author":"Saleem","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.03.027_b0260","doi-asserted-by":"crossref","first-page":"e534","DOI":"10.1016\/S2214-109X(16)30075-4","article-title":"Safety and immunogenicity of inactivated poliovirus vaccine when given with measles-rubella combined vaccine and yellow fever vaccine and when given via different administration routes: a phase 4, randomised, non-inferiority trial in The Gambia","volume":"4","author":"Clarke","year":"2016","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.vaccine.2022.03.027_b0265","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s12879-016-1465-7","article-title":"Characterization of outbreak response strategies and potential vaccine stockpile needs for the polio endgame","volume":"16","author":"Duintjer Tebbens","year":"2016","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2022.03.027_b0270","unstructured":"Global Polio Eradication Initiative. GPEI tools, protocols and guidelines. Available at http:\/\/polioeradication.org\/. Accessed 16 April 2018."},{"key":"10.1016\/j.vaccine.2022.03.027_b0275","first-page":"589","article-title":"Evaluation of house-to-house versus fixed-site oral poliovirus vaccine delivery strategies in a mass immunization campaign in Egypt","volume":"73","author":"Linkins","year":"1995","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.vaccine.2022.03.027_b0280","doi-asserted-by":"crossref","first-page":"859","DOI":"10.15585\/mmwr.mm6533a5","article-title":"Fractional-dose inactivated poliovirus vaccine immunization campaign - Telangana State, India, June 2016","volume":"65","author":"Bahl","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2022.03.027_b0285","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1016\/j.vaccine.2019.12.059","article-title":"Needle-free injectors for mass administration of fractional dose inactivated poliovirus vaccine in Karachi, Pakistan: a survey of caregiver and vaccinator acceptability","volume":"38","author":"Daly","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.03.027_b0290","doi-asserted-by":"crossref","first-page":"690","DOI":"10.15585\/mmwr.mm6724a5","article-title":"Strategic response to an outbreak of circulating vaccine-derived poliovirus type 2 - Syria, 2017\u20132018","volume":"67","author":"Mbaeyi","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2022.03.027_b0295","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.15585\/mmwr.mm6647a4","article-title":"Fractional-dose inactivated poliovirus vaccine campaign - Sindh Province, Pakistan, 2016","volume":"66","author":"Pervaiz","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2022.03.027_b0300","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1016\/j.vaccine.2017.04.075","article-title":"Needle adapters for intradermal administration of fractional dose of inactivated poliovirus vaccine: evaluation of immunogenicity and programmatic feasibility in Pakistan","volume":"35","author":"Saleem","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.03.027_b0305","first-page":"237","article-title":"Combined use of inactivated and oral poliovirus vaccines in refugee camps and surrounding communities - Kenya, December 2013","volume":"63","author":"Sheikh","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2022.03.027_b0310","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1093\/clinids\/2.2.243","article-title":"Eradication of poliomyelitis in the United States II. Experience with killed poliovirus vaccine","volume":"2","author":"Salk","year":"1980","journal-title":"Rev Infect Dis"},{"key":"10.1016\/j.vaccine.2022.03.027_b0315","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(94)92091-5","article-title":"Poliomyelitis outbreak in an unvaccinated community in the Netherlands, 1992\u201393","volume":"344","author":"Oostvogel","year":"1994","journal-title":"The Lancet"},{"key":"10.1016\/j.vaccine.2022.03.027_b0320","doi-asserted-by":"crossref","first-page":"20709","DOI":"10.2807\/1560-7917.ES2014.19.7.20709","article-title":"Molecular epidemiology of silent introduction and sustained transmission of wild poliovirus type 1, Israel, 2013","volume":"19","author":"Shulman","year":"2014","journal-title":"Euro Surveill"},{"key":"10.1016\/j.vaccine.2022.03.027_b0325","doi-asserted-by":"crossref","first-page":"489","DOI":"10.15585\/mmwr.mm6916a1","article-title":"Update on vaccine-derived poliovirus outbreaks - worldwide, July 2019-February 2020","volume":"69","author":"Alleman","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2022.03.027_b0330","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.3201\/eid2411.180050","article-title":"Effect of inactivated poliovirus vaccine campaigns, Pakistan, 2014\u20132017","volume":"24","author":"Grassly","year":"2018","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2022.03.027_b0335","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1111\/risa.12962","article-title":"Modeling poliovirus transmission in Pakistan and Afghanistan to inform vaccination strategies in undervaccinated subpopulations","volume":"38","author":"Duintjer Tebbens","year":"2018","journal-title":"Risk Anal"},{"key":"10.1016\/j.vaccine.2022.03.027_b0340","first-page":"1","article-title":"Costs and benefits of including inactivated in addition to oral poliovirus vaccine in outbreak response after cessation of oral poliovirus vaccine use","volume":"2","author":"Duintjer Tebbens","year":"2017","journal-title":"MDM Policy & Pract"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22003048?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22003048?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:24:01Z","timestamp":1759404241000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22003048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":68,"alternative-id":["S0264410X22003048"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.03.027","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Review of use of inactivated poliovirus vaccine in campaigns to control type 2 circulating vaccine derived poliovirus (cVDPV) outbreaks","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.03.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}